The Radiochemistry and Instrumentation Support Laboratory (RISL) is one of the core facilities and shared resources of The Ohio State University (OSU) Comprehensive Cancer Center (CCC). The purposes of the RISL are fivefold: (1) to provide custom synthesis of radiochemicals not available commercially to investigators of the OSUCCC, (2) to perform purification of custom preparations of chemically-labile radiochemicals, (3) to aid in the purchase of radiochemicals, advice on the use of radiochemical products and equipment, and provide radiation safety expertise to the CCC, (4) to provide organic chemical support services [synthesis, isolation, structure determination, chemistry expertise] for CCC investigators, and (5) to maintain chemical instrumentation for the isolation and structure determination of carcinogens, drugs, metabolites, and biochemical compounds and general equipment for biochemical/biological research. Robert W. Brueggemeier, Ph.D. is director of the Radiochemistry and Instrumentation Support Laboratory and is involved with projects both as a shared resource person and as a principal investigator within he OSUCCC. Michael V. Darby, Ph.D. serves as the full-time synthetic radiochemist in the Radiochemistry Laboratory. Drs. Brueggemeier and Darby co-direct a graduate research assistant and work closely with cost doctoral research and technicians on the various projects utilizing radiochemistry and chemistry services. Several research and service activities were expanded or introduced since July 1995. These additional services include development of methods of determination of 8-hydroxydeoxyguanosine levels by HPLC- electrochemical detection, expansion of iodination procedures using a variety of reagents, acquisition and installation of new instrumentation and relocation of instruments into laboratory facilities where the instruments are more effectively utilized. The RISL will continue to be an effective radiochemistry and instrumentation support facility for cancer research, diagnosis, or treatment that is encompassed in the OSU Comprehensive Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-27
Application #
6563730
Study Section
Project Start
2001-12-01
Project End
2002-11-30
Budget Start
Budget End
Support Year
27
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
White, Brian S; Lanc, Irena; O'Neal, Julie et al. (2018) A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer J 8:35
Owen, Dwight; Chaft, Jamie E (2018) Immunotherapy in surgically resectable non-small cell lung cancer. J Thorac Dis 10:S404-S411
O'Brien, Susan M; Jaglowski, Samantha; Byrd, John C et al. (2018) Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. JAMA Oncol 4:712-716
Guo, Sijin; Piao, Xijun; Li, Hui et al. (2018) Methods for construction and characterization of simple or special multifunctional RNA nanoparticles based on the 3WJ of phi29 DNA packaging motor. Methods 143:121-133
Sadowski, Abbey R; Gardner, Heather L; Borgatti, Antonella et al. (2018) Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma. BMC Vet Res 14:250
Barredo, Julio C; Hastings, Caroline; Lu, Xiamin et al. (2018) Isolated late testicular relapse of B-cell acute lymphoblastic leukemia treated with intensive systemic chemotherapy and response-based testicular radiation: A Children's Oncology Group study. Pediatr Blood Cancer 65:e26928
Kim, So-Youn; Nair, Devi M; Romero, Megan et al. (2018) Transient inhibition of p53 homologs protects ovarian function from two distinct apoptotic pathways triggered by anticancer therapies. Cell Death Differ :
Yadav, Marshleen; Song, Feifei; Huang, Jason et al. (2018) Ocimum flavone Orientin as a countermeasure for thrombocytopenia. Sci Rep 8:5075
Farquhar, Neil; Thornton, Sophie; Coupland, Sarah E et al. (2018) Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. J Pathol Clin Res 4:26-38

Showing the most recent 10 out of 2602 publications